Singapore approves Pfizer's oral COVID-19 medicine Paxlovid
Singapore has approved Pfizer's (PFE.N) oral COVID-19 medicine Paxlovid, its Health Sciences Authority (HSA) said on Thursday. Paxlovid is the first COVID-19 oral treatment authorised for use in the city-state for the treatment of mild to moderate cases among adults at high risk of severe disease, HSA said in a statement.
View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/singapore-approves-pfizers-oral-covid-19-medicine-paxlovid-2022-02-03/